Ingenia Therapeutics Passes KOSDAQ Listing Preliminary Review…Expectations Rise
Ingenia Therapeutics has passed the preliminary review for KOSDAQ listing, officially beginning its IPO process, with its technology and growth potential being highlighted.
Get the next 8/10 catalyst
Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 51.8%.
Get high-impact news instantly
Top stories with score 8/10+ delivered to your Telegram in real time. Free.
Join Telegram channel